IMRICOR MEDICAL SYSTEMS INC (IMR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMR

IMR - IMRICOR MEDICAL SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.15
Index: ASX300 | ALL-ORDS

Imricor Medical Systems develops MRI-compatible equipment for cardiac catheter ablation, allowing clinicians to perform heart rhythm procedures using real-time MRI guidance.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.43

16 Oct
2026

-0.020

OPEN

$1.44

-1.38%

HIGH

$1.49

524,282

LOW

$1.42

TARGET
$2.90 102.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SLD . SOM . TRJ .
FNARENA'S MARKET CONSENSUS FORECASTS
IMR: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 10.5 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-12.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.5 M
Book Value Per Share xxxxxxxxxxxxxxx5.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-29.6 M
Net Profit Margin xxxxxxxxxxxxxxx-8,661.57 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1,463.63 %
Return on Invested Capital xxxxxxxxxxxxxxx-131.50 %
Return on Assets xxxxxxxxxxxxxxx-75.84 %
Return on Equity xxxxxxxxxxxxxxx-1,463.63 %
Return on Total Capital xxxxxxxxxxxxxxx-89.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx18 M
Long Term Debt xxxxxxxxxxxxxxx21 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx61 M
Price To Book Value xxxxxxxxxxxxxxx28.42

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.7 M
Capex % of Sales xxxxxxxxxxxxxxx148.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx4 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx17 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

01/10/2026

1

Speculative Buy

$2.90

102.80%

Imricor Medical Systems has experienced a drop of over -20% in its share price since entering the ASX300 index in early September and Morgans considers this a "great buying opportunity".

Recent news has been positive and further milestones are expected to be announced over the next 3-6 months. Catalysts include NorthStar orders, clinical data submissions, European/ME sales and FDA approvals.

The broker suggests seasonal weakness and a rising interest-rate environment may have contributed to the fall but, as a seasonally stronger part of the year materialises, the share price should move back over $2.00.

Target is $2.90. Speculative Buy retained.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -10.51 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -5.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Taylor Collison

07/09/2026

2

Outperform & Accumulate

$3.40

137.76%

Taylor Collison maintains an Outperform rating for Imricor Medical Systems with its target price increased to $3.40 following the receipt of a paediatric NorthStar purchase order from Rady Children's Hospital.

The analyst views the order as primary evidence of demand for MRI-guided procedures in children, where an unmet need to eliminate ionising radiation exposure exists.

With several additional US hospitals in the final stages of the purchasing process, Taylor Collison expects up to three paediatric purchase orders to be brought forward in 2026.

Building on commercial and regulatory momentum, the company launched Imricor Cardiovascular to target the cardiac catheterisation market alongside its electrophysiology business.

Upcoming catalysts include the VISABL-AFL trial readout by mid-September, enabling FDA submission and subsequent commercialisation shortly after the end of the second quarter of 2027, according to Taylor Collison.

FORECAST
Taylor Collison forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -16.98 cents.
Taylor Collison forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -13.96 cents.

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IMR STOCK CHART

FNArena News on IMR

1
Australian Broker Call *Extra* Edition – Oct 19, 2026

Oct 19 2026 - Daily Market Reports
2
Rudi’s View: Stocks To Own & Best To Avoid

Oct 15 2026 - Rudi's View
3
Rudi’s View: Ampol, BlueScope, Evolution, Infratil, Ramelius & More

Sep 24 2026 - Rudi's View
4
Rudi’s View: Australia Remains Outside The AI Party

Sep 09 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Sep 07, 2026

Sep 07 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Vitrafy Eyes US Blood Breakthrough

Oct 06 2026 - Small Caps
2
Undervalued Catapult Sports Plays A Bigger Game

Sep 16 2026 - Small Caps
3
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
4
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
5
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
6
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
7
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
8
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
9
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
10
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps